Aaron G.L. Fletcher sold $247k of LTRN
owner at Lantern Pharma Inc.. 58,889 shares at an average of $4.20, traded Jan 17, 2024, filed Jan 19, 2024.
Score components
- +12Role10% owner
- +13Trade size$247k at market
- +20Share of holdings soldSold 74% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-005242, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 17, 2024 | XIn-the-money exercise Common Stockindirect: By Bios Fund II NT, LP | +7,347 | $3.13 | $23k | 79,121 | Jan 19, 2024 |
| Jan 17, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -5,475 | $4.20 | $23k | 73,646 | Jan 19, 2024 |
| Jan 17, 2024 | XIn-the-money exercise Common Stockindirect: By Bios Fund II QP, LP | +54,873 | $3.13 | $172k | 591,036 | Jan 19, 2024 |
| Jan 17, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -40,893 | $4.20 | $172k | 550,143 | Jan 19, 2024 |
| Jan 17, 2024 | XIn-the-money exercise Common Stockindirect: By Bios Fund II, LP | +16,801 | $3.13 | $53k | 180,938 | Jan 19, 2024 |
| Jan 17, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -12,521 | $4.20 | $53k | 168,417 | Jan 19, 2024 |
| Jan 17, 2024 | XIn-the-money exercise Series A Warrantsderivativeindirect: By Bios Fund II NT, LP | -7,347 | $0.00 | $0 | 0 | Jan 19, 2024 |
| Jan 17, 2024 | XIn-the-money exercise Series A Warrantsderivativeindirect: By Bios Fund II QP, LP | -54,873 | $0.00 | $0 | 0 | Jan 19, 2024 |
| Jan 17, 2024 | XIn-the-money exercise Series A Warrantsderivativeindirect: By Bios Fund II, LP | -16,801 | $0.00 | $0 | 0 | Jan 19, 2024 |
Related signals
Other insiders at Lantern Pharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Lantern Pharma Inc. | D Jeffrey Keyser director | $100k 48,544 shares | +106% | |
| 49Moderate | Lantern Pharma Inc. | Lee Troy Schalop director | $100k 48,544 shares | - | |
| 42Moderate | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $208k 61,613 shares | -30% | |
| 35Weak | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $124k 40,000 shares | -20% | |
| 42Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $208k 61,613 shares | -30% | |
| 35Weak | Lantern Pharma Inc. | Leslie W. Kreis owner | $124k 40,000 shares | -20% | |
| 41Moderate | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $168k 56,237 shares | -26% | |
| 41Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $168k 56,237 shares | -26% | |
| 42Moderate | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $189k 30,000 shares | -50% | |
| 42Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $189k 30,000 shares | -50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.